TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31624837
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg once daily for 16 weeks
Study: 30073766
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 16 weeks
Study: 31912462
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg once daily
Study: 31411762
Drug: DEX infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX infusion 0.5 μg/kg after delivery and PCIA with DEX plus sufentanil
Study: 31411762
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (infusion with 0.9% normal saline after delivery and PCIA with sufentanil)
Study: 28146613
Drug: Aripiprazole Once-Monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole Once-Monthly 400 mg (AOM 400)
Study: 21724580
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2 g/d)
Study: 17492350
Drug: Conjugated Hib
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated Hib vaccine
Study: 15145966
Drug: Anidulafungin 50
Normalized name: anidulafungin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin 50 mg, 75 mg, or 100 mg daily intravenous infusions preceded by a loading dose that was twice the daily dose.
Study: 8770428
Drug: Regular neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular neuroleptic medication
Study: 18245030
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from medication
Study: 678769
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic cover
Study: 19294859
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy group
Study: 17933158
Drug: Milrinone (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (bolus and infusion throughout surgery)
Study: 12149533
Drug: AS+NRT (Nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS+NRT (Nicotine patches daily and inhalator as needed plus advice and support)
Study: 1934240
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg body weight twice daily) for 1 day (3 doses)
Study: 1934240
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg body weight twice daily) for 2 days
Study: 1934240
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg body weight twice daily) for 4 days
Study: 1934240
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg body weight twice daily) for 7 days
Study: 7106043
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 20-percent lipofundin followed by ergometer load (group II)
Study: 7106043
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of lipofundin without subsequent physical stress (group III)
Study: 27085783
Drug: Metformin 850mg
Normalized name: METFORMIN 850MG/PIOGLITAZONE 15MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850mg twice daily
Study: 21592974
Drug: UACR in
Approvals — FDA: no, EMA: no, PMDA: no
Description: UACR in the fourth quartile (≥ 6.1 mg/g)
Study: 21592974
Drug: UACR in
Approvals — FDA: no, EMA: no, PMDA: no
Description: UACR in the third quartile (3.8-6.1 mg/g)
Study: 21592974
Drug: UACR in
Approvals — FDA: no, EMA: no, PMDA: no
Description: UACR in the lowest quartile (<2.8 mg/g)
Study: 17122382
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 5 mg twice daily
Study: 17122382
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 10 mg twice daily
Study: 9558692
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy for rate control
Study: 9558692
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy for rhythm control
Study: 9558692
Drug: Drug selection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug selection algorithm for rate control
Study: 24460645
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily for 35 ± 4 days
Study: 31655496
Drug: Prednisone administration
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone administration
Study: 31655496
Drug: Prednisolone administration
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone administration
Study: 26674499
Drug: Daily 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 400 IU vitamin D supplementation
Study: 16243339
Drug: Calcium (600
Normalized name: calcium carbonate/vitamin D3 250 mg calcium (600 mg)-125 unit ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (600 mg) plus CLA (450 mg)
Study: 10333943
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of family history, fasting glucose, and total proinsulin
Study: 2190549
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pyridostigmine bromide every 8 h
Study: 379704
Drug: Carfecillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfecillin (250 mg and 500 mg p.o.)
Study: 27123977
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy based on the catastrophic cognitions model of PDA
Study: 27123977
Drug: Guided mastery
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided mastery (guided exposure) therapy based on the self-efficacy model of PDA
Study: 9892856
Drug: Amisulpride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50 mg/day)
Study: 9892856
Drug: Amineptine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amineptine (200 mg/day)
Study: 2572494
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg etizolam
Study: 28698258
Drug: Standard-dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose enoxaparin
Study: 26408319
Drug: Yerba Mate
Normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yerba Mate supplementation (3 g/day, 3 capsules per meal, 3 times a day for 12 weeks)
Study: 23506627
Drug: Residual protein/creatinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual protein/creatinine ratio (rPCR) <1000 mg/g
Study: 23506627
Drug: Residual estimated
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual estimated glomerular filtration rate (reGFR) ≥45 mL/min per 1.73 m2
Study: 23506627
Drug: Residual protein/creatinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual protein/creatinine ratio (rPCR) between 1000-<2000 mg/g and reGFR ≥30 mL/min per 1.73 m2
Study: 23506627
Drug: Residual estimated
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual estimated glomerular filtration rate (reGFR) <30 mL/min per 1.73 m2 and rPCR ≥2000 mg/g
Study: 19445552
Drug: Sublingual morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual morphine sulphate 0.5 mg/kg (Group A)
Study: 19445552
Drug: Sublingual midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual midazolam 0.03 mg/kg (Group B)
Study: 18508950
Drug: Taranabant 5
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 5 mg once daily for 14 days
Study: 18508950
Drug: Taranabant 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 7.5 mg once daily for 14 days
Study: 18508950
Drug: Taranabant 10
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 10 mg once daily for 14 days
Study: 18508950
Drug: Taranabant 25
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 25 mg once daily for 14 days
Study: 16077888
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and G-CSF (group A)
Study: 16077888
Drug: Antibiotics only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics only (group B)
Study: 8829859
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg.kg-1
Study: 7484022
Drug: Adenosine 50
Normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 50 micrograms.kg-1.min-1 + Morphine 0.1 mg.kg-1
Study: 7484022
Drug: Ketamine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.1 mg.kg-1
Study: 15533378
Drug: Low-molecular-weight dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight dextran (Dextran 40) infusion
Study: 15533378
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin infusion
Study: 2904839
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet alone (Group 1)
Study: 2904839
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet with 150 ml oral fluid (Group 3)
Study: 2904839
Drug: Oral ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine 150 mg with oral fluid 150 ml (Group 4)
Study: 2904839
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet with IM narcotic and atropine (Group 2)
Study: 17561543
Drug: Indiplon 15
Normalized name: Indiplon
DrugBank: Indiplon (DB12590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indiplon 15 mg nightly
Study: 10697305
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 16 mg once daily for 6 weeks
Study: 9108638
Drug: Ropivacaine hydrochloride
Normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine hydrochloride 20 mg
Study: 9108638
Drug: Ropivacaine hydrochloride
Normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine hydrochloride 40 mg
Study: 9108638
Drug: Ropivacaine hydrochloride
Normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine hydrochloride 80 mg
Study: 3814215
Drug: Amcinonide, betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amcinonide, betamethasone 17-valerate, triamcinolone acetonide (alcoholic solutions)
Study: 3814215
Drug: Clobetasol 17-propionate
Normalized name: clobetasol 17-propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol 17-propionate (ointment)
Study: 27156228
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (M)
Study: 27156228
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and morphine (AM)
Study: 25336916
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg (single oral dose)
Study: 20825523
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg) daily for 3 months
Study: 18315942
Drug: Fixed-combination bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-combination bimatoprost 0.03%/timolol 0.5% administered once daily
Study: 18315942
Drug: Fixed-combination travoprost/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination travoprost/timolol
Study: 19692375
Drug: Fixed-combination latanoprost/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination latanoprost/timolol
Study: 14706505
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist therapy (immediate adjuvant therapy after prostatectomy)
Study: 14706505
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with radiation
Study: 14706505
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade (LHRH agonist + nonsteroidal antiandrogen)
Study: 14706505
Drug: Intermittent hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent hormone therapy
Study: 14706505
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist therapy
Study: 28964314
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg rocuronium
Study: 12017979
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg rocuronium
Study: 10998836
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg rocuronium (females)
Study: 10998836
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium (females)
Study: 10998836
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg rocuronium (females)
Study: 10998836
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg rocuronium (males)
Study: 10998836
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg rocuronium (males)
Study: 10998836
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg rocuronium (males)
Study: 8844446
Drug: Felbamate (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbamate (1,200 mg every 12 hours)
Study: 30359684
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg twice daily for seven days
Study: 24121083
Drug: Ultrasound-guided SIJ
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided SIJ injections
Study: 24121083
Drug: Fluoroscopy-guided SIJ
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy-guided SIJ injections
Study: 22682323
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg three times a week
Study: 18076292
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (80 mg/12 h)
Study: 18076292
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg/12 h)
Study: 9005613
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (thrombolytic drugs, beta‐blockers, APP inhibitors, nitrates, aspirin)
Study: 6979982
Drug: Propranolol 10
Normalized name: propranolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 10 mg every 6 hours enterally starting the morning after surgery (Group I, 50 patients)
Study: 30120033
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (MT) program for sensori‐motor impairment
Study: 18502028
Drug: Propiverine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine (10 or 15 mg twice daily)
Study: 17944740
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. + Placebo
Study: 17944740
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. + Ranitidine 300 mg at bedtime
Study: 15854087
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral prednisolone once daily perioperatively (Group I, n = 20)
Study: 12408530
Drug: Induction group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction group (IFN 3 MU daily for 14 days, then 3 MU three times a week)
Study: 10225553
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (treatment duration up to 48 days)
Study: 10225553
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (treatment duration 49 or more days)
Study: 7869940
Drug: dF 30
Normalized name: AlleRx DF 30-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: dF 30 mg acutely (n = 6)
Study: 7869940
Drug: dF 15
Normalized name: Adriamycin RDF 150mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: dF 15 mg twice daily for 15 days (chronic)
Study: 31607604
Drug: Oral poliovirus
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral poliovirus vaccine (OPV) co-administered with RV3-BB
Study: 31607604
Drug: Inactivated polio
Normalized name: Inactivated polio vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated polio vaccine (IPV) co-administered with RV3-BB
Study: 7747098
Drug: Oral poliovirus
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral poliovirus vaccine (OPV)
Study: 26242222
Drug: Test capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test capecitabine tablets (T)
Study: 26242222
Drug: Reference capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference capecitabine tablets (R)
Study: 24041978
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (E+P) therapy
Study: 16217004
Drug: Obstetrician/gynecologists and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstetrician/gynecologists and family medicine physicians
Study: 10366230
Drug: Generalized chronic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized chronic inflammatory demyelinating polyneuropathy (G-CIDP)
Study: 7717597
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with antimicrobial therapy for 7 days
Study: 2392131
Drug: trimethoprim-sulfamethoxazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim-sulfamethoxazole (20 and 100 mg per kilogram of body weight per day)
Study: 2392131
Drug: trimethoprim-dapsone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim-dapsone (20 mg per kilogram per day and 100 mg per day)
Study: 31156265
Drug: Karo Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karo Light syrup
Study: 31156265
Drug: Crown Lily
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crown Lily White syrup
Study: 29040837
Drug: Grape intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape intake (5 g/kg body weight/day for 3 weeks)
Study: 26611434
Drug: 100mg enteric-coated
Normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg enteric-coated aspirin
Study: 19390079
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy during coiling
Study: 19390079
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy after coiling
Study: 19390079
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy during coiling
Study: 19390079
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy after coiling
Study: 17272770
Drug: Above median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Above median hsCRP level (> or =0.21 mg/L)
Study: 16276447
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL 2% lidocaine and 0.5 mL betamethasone (7 mg/mL)
Study: 16276447
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL 1% lidocaine and 0.5 mL betamethasone (7 mg/mL)
Study: 26938637
Drug: Ginkgo Biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Biloba (120 mg, 240 mg)
Study: 26938637
Drug: Ginseng (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (500 mg, 1000 mg)
Study: 23176985
Drug: G1: hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1: hyperbaric bupivacaine (8 mg), sufentanil (2.5 μg), morphine (100 μg)
Study: 23176985
Drug: G2: hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: G2: hyperbaric bupivacaine (10 mg), sufentanil (2.5 μg), morphine (100 μg)
Study: 23176985
Drug: G3: hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: G3: hyperbaric bupivacaine (12.5 mg), morphine (100 μg)
Study: 23176985
Drug: G4: hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: G4: hyperbaric bupivacaine (15 mg), morphine (100 μg)
Study: 23176985
Drug: G5: hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: G5: hyperbaric bupivacaine (12.5 mg), morphine (100 μg), without perioperative anti‐inflammatory
Study: 12145066
Drug: Isoflurane inhalation
Normalized name: isoflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhalation
Study: 12145066
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isoflurane and propofol
Study: 7308277
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg once/day
Study: 7308277
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg twice/day